🔎 Trials Near Me

Utama › Kanser Paru-paru Sel Kecil › California › Los Angeles

Kajian klinikal Kanser Paru-paru Sel Kecil di Los Angeles, CA

20 kajian untuk Kanser Paru-paru Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Los Angeles (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Mengambil pesertaFasa 1/2
  • UCLA Jonsson Comprehensive Cancer Center, Los Angeles
  • USC Norris Comprehensive Cancer Center, Los Angeles
Umur 12 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Mengambil pesertaFasa 1
  • University of California - Los Angeles, Los Angeles
Umur 19 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06586957

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

Mengambil pesertaFasa 3
  • GSK Investigational Site, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07099898

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Mengambil pesertaFasa 1/2
  • University of Southern California, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06047379

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Mengambil pesertaFasa 1/2
  • START Los Angeles, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07488676

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Mengambil pesertaFasa 2
  • Valkyrie Clinical Trials, Inc., Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07459634

BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

Mengambil pesertaFasa 3
  • Valkyrie Clinical Trials, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07625644

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Mengambil pesertaFasa 1/2
  • Avenzo Therapeutics Recruiting Site, Los Angeles
  • Avenzo Therapeutics Recruiting Site, Los Angeles
Umur 18 hingga 75 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07038343

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Mengambil pesertaFasa 1/2
  • University of California LA, Los Angeles
Umur 18 hingga 100 · Semua jantina · Dikemas kini 27 Ogo 2026 · NCT06726148

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Mengambil pesertaFasa 1/2
  • Cedars Sinai Medical Center, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06892548

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

Mengambil pesertaFasa 1
  • University of Southern California, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT06922539

A Study of MGC026 in Participants With Advanced Solid Tumors

Mengambil pesertaFasa 1
  • The Angeles Clinic and Research Institute, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT06242470

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Mengambil pesertaFasa 3
  • UCLA Hematology-Oncology, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06203210

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Mengambil pesertaFasa 2
  • Valkyrie Clinical Trials, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Jul 2026 · NCT05882058

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Mengambil pesertaFasa 1/2
  • USC Norris Comprehensive Cancer Center, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT05652686

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Mengambil pesertaFasa 1
  • University of Southern California, Norris Comprehensive Cancer Center, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Jun 2026 · NCT06598306

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

Mengambil pesertaFasa 1
  • Start Lacn, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Jun 2026 · NCT07517198

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Mengambil peserta
  • Oncology Institute for Hope and Innovation, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Apr 2026 · NCT05297734

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Mengambil pesertaFasa 1/2
  • Research Site 125, Los Angeles
  • Research Site 133, Los Angeles
  • Research Site 103, Los Angeles
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Nov 2025 · NCT05914116

Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Mengambil pesertaFasa 2
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Semua umur · Semua jantina · Dikemas kini 17 Nov 2025 · NCT05588388

Kajian Kanser Paru-paru Sel Kecil di bandar lain

Kajian lain di Los Angeles

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.